SlideShare a Scribd company logo
1 of 31
Do’s and Don’ts
During An FDA Inspection
Copyrighted 2013 Compliance Insight, Inc.
When dealing with the FDA investigator,
we should demonstrate knowledge of and
confidence in our quality system.
Not arrogant nor defiant…
The DO’s During an Inspection
Copyrighted 2013 Compliance Insight, Inc.
* Never give false data, always tell
the truth
* Is it OK to say “I don’t know”?
* The investigator may ask the same
question to different people at
different times
The DON’Ts During an Inspection
Copyrighted 2013 Compliance
Insight, Inc.
The DON’Ts During an Inspection
 There are some “tricks”
used to pull information
from you during the
audit
 Be aware of what you are
saying and doing
 The “dome of silence”
 The tendency of people
to try to fill a void with
more information
 Talk, offer more info
 The “Hmmm… factor”
 Ask a question, write it
down, shake your head or
get a concerned look
 People take this as a
“problem” and then offer
more info to fill the gap
Copyrighted 2013 Compliance
Insight, Inc.
If the investigator asks you for
some information, do not:
* make them ask for it again
* wait to see if they forget about
the request
The DON’Ts During an Inspection
Copyrighted 2013 Compliance
Insight, Inc.
* It is not productive to argue with the investigator
when responding to a question or observation
* Don’t challenge the investigator. There is no
need for that. It only motivates curiosity and
questions.
The DON’Ts During an Inspection
Copyrighted 2013 Compliance Insight, Inc.
* Do not stand around making faces and looking
worried. This makes people feel nervous and may
alert the investigator that something may be
wrong.
* Act confident and proud, not defensive.
* If a fellow employee is being questioned, do not try
to help them by answering the questions yourself or
by giving contradictory information.
The DON’Ts During an Inspection
Copyrighted 2013 Compliance Insight, Inc.
* Do not interrupt the investigator or other
employees when they are speaking
* Do not talk loud or speak with the others
when the investigator is trying to
concentrate, read or review documentation.
* It is not your job to fill an uncomfortable
silence with additional explanation.
The DON’Ts During an Inspection
Copyrighted 2013 Compliance Insight, Inc.
The DON’Ts During an Inspection
Loos
e
lips
sink
ships
Don’t talk – even off
site!!! Copyrighted 2013 Compliance Insight, Inc.
Things To Remember
During An FDA Inspection
Copyrighted 2013 Compliance Insight, Inc.
* If it isn’t documented, it
doesn’t exist
Things to Remember During an Audit
Copyrighted 2013 Compliance
Insight, Inc.
* Investigator may
“read” your body
language
* Be aware of your
body language
Things to Remember During an Audit
Copyrighted 2013 Compliance
Insight, Inc.
* During the inspection,
observe and learn to
“read” the Investigator’s
body language.
Things to Remember During an Audit
Copyrighted 2013 Compliance
Insight, Inc.
* Verbal ~7%
* Paralinguistic ~38%
* Non-Verbal ~55%
Communication
Copyrighted 2013 Compliance
Insight, Inc.
* Intimate zone 0-1½ ft.
* Personal zone1½-4 ft.
* Social zone 4-12 ft.
Interview Orientation
Copyrighted 2013 Compliance
Insight, Inc.
* Establish the “normal” behavior patterns
So that you are aware of behavioral changes
Interview Techniques
Copyrighted 2013 Compliance
Insight, Inc.
* Upright
* Open & Relaxed
* Lean forward on occasion
* Aligned with Investigator
* Casual Posture Change
Truthful Posture
Copyrighted 2013 Compliance
Insight, Inc.
* Retreating
* Slouching
* Frozen
* Not aligned
* Barrier Posture
* Consistent posture changes
* Head & Body Slump
Deceptive Posture
Copyrighted 2013 Compliance
Insight, Inc.
* Composed
* Concerned/Realistic
* Cooperative
* Direct/Spontaneous
* Open/Helpful
* Sincere
* Confident
* Persistent/Consistent
Truthful Behaviors
Copyrighted 2013 Compliance
Insight, Inc.
* Overly Anxious
* Unconcerned/Unrealistic
* Uncooperative/Defensive
* Guarded/Evasive/Hesitant
* Rationalizing/Unhelpful
* Insincere
* Defeated
* Apologetic/Accepting
* Quiet
Deceptive Behaviors
Copyrighted 2013 Compliance
Insight, Inc.
Breaking a Gaze
Right = edit or
fabricate
Left = access memory
I wonder if
he’ll
believe
this?
Yes, that is
how it was
done
About 85%
accurate but
use only as a
tool to
determine if
further
questions
need to beCopyrighted 2013 Compliance
Insight, Inc.
* Stick to the facts not opinions. Do not use
phrases such as:
I think …
I’m not sure but …
In my opinion, it should …
What you are saying is not true…
Honestly… Usually… Typically…
As I recall…
Things to Remember During an Audit
Copyrighted 2013 Compliance Insight, Inc.
* Listen to questions carefully
* Answer only what is asked. Do not volunteer
information
* Clarify what you don’t understand before
answering the question
* When a question is too broad, ask for specifics
Things to Remember During an Audit
Copyrighted 2013 Compliance
Insight, Inc.
* If you don’t know the answer, say so. It is all
right to say that you need to look into the
situation further before answering.
* Do not guess if you’re not sure of the answer.
Look it up in the procedure and or consult you
peers, or another SME.
* If you are not a SME for a question asked, do not
answer the question and explain to FDA this fact
and get the right person.
Things to Remember During an Audit
Copyrighted 2013 Compliance Insight, Inc.
If you think that the investigator has misunderstood
something
* say so immediately
* explain why in a professional manner
Things to Remember During an Audit
Copyrighted 2013 Compliance Insight, Inc.
Phrases to Refrain From!
* That’s the way we’ve always done it
* Off the record…
* I probably shouldn’t say this but…
* Who, me?
* … Uh, no
* It’s probably a mistake.
Copyrighted 2013 Compliance Insight, Inc.
* If we would do it that way we would never get anything done
* We don’t have enough time or resources to follow that procedure
* I do it a different way because the procedure is not good
* If you think that’s bad you should see this...
* We fixed that problem by firing the person
* That’s not my fault, that was the previous supervisor …
* That’s not my problem, that’s Quality Assurance’s problem
* Write it on the FDA-483, it’s the only way we can correct it.
Phrases to Refrain From!
Copyrighted 2013 Compliance Insight, Inc.
Documents and Records
The investigator is permitted to review :
 Documents and records pertaining to
the control, manufacturing or quality
assurance activities within the facility,
as required by applicable federal
regulations.
 These include (but are not limited to):
 Procedures
 Batch Records
 Regulatory Filings
 Quality Control Procedures
 Validation records
 Calibration/PM records
 Investigations
 Other records such as training
records, job descriptions,
procedures, promotional labeling
etc., as defined in relevant parts
of the FDA regulation unless
otherwise specified.
Documents that can not be reviewed
by FDA:
 Reports of audits performed by
internal auditors, customers,
external auditors or consultants
 Records and documents
pertaining to the financial
matters of the company (sales
data, pricing information, etc.)
 Research data/protocols (true
“research” data is exempt from
review, product development
data can be reviewed by FDA)
 Personnel records other than
training
 Management review meeting
minutes
Copyrighted 2013 Compliance Insight, Inc.
What happens if an investigator finds something wrong?
Answer:
 Discuss concern/finding with investigator so you fully understand
what the investigator understands. There should be no
misconceptions. Ask questions.
 At the end of each day, we request an oral list of all observations.
This gives us an opportunity to address issues before the close of
the inspection and allows us to prepare responses to potential 483
observations.
 At the conclusion of the inspection, the investigator presents
significant findings at the closing meeting on a FDA 483, List of
Observations.
 If the findings are minor, the investigator may opt to do nothing
except verbally advise the Regulatory representative and
management of the concerns.
Frequently Asked Questions
Copyrighted 2013 Compliance Insight, Inc.
What happens if an investigator find something wrong?
Answer (continued):
 Your firm will respond in writing to the Form 483 with a
corrective action plan.
 We have to act quickly but effectively.
 Corrective Action Plan should address specific
observations, systemic correction and time frame for
implementing corrective actions.
Frequently Asked Questions
Copyrighted 2013 Compliance Insight, Inc.
Compliance Insight, Inc.
513-860-3512
For a Free Consultation
www.Compliance-Insight.com
Copyrighted 2013 Compliance Insight, Inc.

More Related Content

What's hot

Deviation and root cause analysis in Pharma
Deviation and root cause analysis in PharmaDeviation and root cause analysis in Pharma
Deviation and root cause analysis in PharmaSubhash Sanghani
 
Quality audit 112070804012
Quality audit 112070804012Quality audit 112070804012
Quality audit 112070804012Patel Parth
 
Handling of OOS Dr.A. Amsavel
Handling of OOS  Dr.A. AmsavelHandling of OOS  Dr.A. Amsavel
Handling of OOS Dr.A. AmsavelDr. Amsavel A
 
Data integrity in Pharmaceutical industry
Data integrity in Pharmaceutical industry Data integrity in Pharmaceutical industry
Data integrity in Pharmaceutical industry GxPProfessional
 
Good Documentation Practices
Good Documentation PracticesGood Documentation Practices
Good Documentation PracticesNikhil Soni
 
FDA Inspections ( How to Survive an FDA Inspection).ppt
FDA Inspections ( How to Survive an FDA Inspection).pptFDA Inspections ( How to Survive an FDA Inspection).ppt
FDA Inspections ( How to Survive an FDA Inspection).pptshaik malangsha
 
Good Documentation Practices -Do's and Don'ts- (GCP)
Good Documentation Practices -Do's and Don'ts- (GCP)Good Documentation Practices -Do's and Don'ts- (GCP)
Good Documentation Practices -Do's and Don'ts- (GCP)Piyush Wagh
 
GMP compliances of Audit
GMP compliances of AuditGMP compliances of Audit
GMP compliances of AuditMegha bhise
 
Data integrity in Pharmaceutical Industries
Data integrity in Pharmaceutical IndustriesData integrity in Pharmaceutical Industries
Data integrity in Pharmaceutical IndustriesS S N D Balakrishna Ch
 
Data Integrity - the ALCOA model
Data Integrity - the ALCOA modelData Integrity - the ALCOA model
Data Integrity - the ALCOA modelpi
 
Ensuring data integrity in pharmaceutical environment
Ensuring data integrity in pharmaceutical environmentEnsuring data integrity in pharmaceutical environment
Ensuring data integrity in pharmaceutical environmentdeepak mishra
 
Data Integrity Issues in Pharmaceutical Companies
Data Integrity Issues in Pharmaceutical CompaniesData Integrity Issues in Pharmaceutical Companies
Data Integrity Issues in Pharmaceutical CompaniesPiyush Tripathi
 
Preparing for an FDA Inspection
Preparing for an FDA InspectionPreparing for an FDA Inspection
Preparing for an FDA InspectionDarshan Kulkarni
 
Data integrity & ALCOA+
Data integrity & ALCOA+Data integrity & ALCOA+
Data integrity & ALCOA+TuhinReza5
 
Good Documentation Practice (GDocP).pdf
Good Documentation Practice (GDocP).pdfGood Documentation Practice (GDocP).pdf
Good Documentation Practice (GDocP).pdfMd. Zakaria Faruki
 
Investigation of OOS and OOT results
Investigation of OOS and OOT resultsInvestigation of OOS and OOT results
Investigation of OOS and OOT resultsMoshfiqur Rahaman
 
Good Documentation Practice
Good Documentation PracticeGood Documentation Practice
Good Documentation PracticeDr. Amsavel A
 

What's hot (20)

Deviation and root cause analysis in Pharma
Deviation and root cause analysis in PharmaDeviation and root cause analysis in Pharma
Deviation and root cause analysis in Pharma
 
ALCOA & ALCOA+
ALCOA & ALCOA+ALCOA & ALCOA+
ALCOA & ALCOA+
 
Quality audit 112070804012
Quality audit 112070804012Quality audit 112070804012
Quality audit 112070804012
 
Handling of OOS Dr.A. Amsavel
Handling of OOS  Dr.A. AmsavelHandling of OOS  Dr.A. Amsavel
Handling of OOS Dr.A. Amsavel
 
Data integrity in Pharmaceutical industry
Data integrity in Pharmaceutical industry Data integrity in Pharmaceutical industry
Data integrity in Pharmaceutical industry
 
Good Documentation Practices
Good Documentation PracticesGood Documentation Practices
Good Documentation Practices
 
Preparing and handling an inspection
Preparing and handling an inspectionPreparing and handling an inspection
Preparing and handling an inspection
 
FDA Inspections ( How to Survive an FDA Inspection).ppt
FDA Inspections ( How to Survive an FDA Inspection).pptFDA Inspections ( How to Survive an FDA Inspection).ppt
FDA Inspections ( How to Survive an FDA Inspection).ppt
 
Good Documentation Practices -Do's and Don'ts- (GCP)
Good Documentation Practices -Do's and Don'ts- (GCP)Good Documentation Practices -Do's and Don'ts- (GCP)
Good Documentation Practices -Do's and Don'ts- (GCP)
 
Handling of Out of Specification Results
Handling of Out of Specification ResultsHandling of Out of Specification Results
Handling of Out of Specification Results
 
GMP compliances of Audit
GMP compliances of AuditGMP compliances of Audit
GMP compliances of Audit
 
Data integrity in Pharmaceutical Industries
Data integrity in Pharmaceutical IndustriesData integrity in Pharmaceutical Industries
Data integrity in Pharmaceutical Industries
 
Data Integrity - the ALCOA model
Data Integrity - the ALCOA modelData Integrity - the ALCOA model
Data Integrity - the ALCOA model
 
Ensuring data integrity in pharmaceutical environment
Ensuring data integrity in pharmaceutical environmentEnsuring data integrity in pharmaceutical environment
Ensuring data integrity in pharmaceutical environment
 
Data Integrity Issues in Pharmaceutical Companies
Data Integrity Issues in Pharmaceutical CompaniesData Integrity Issues in Pharmaceutical Companies
Data Integrity Issues in Pharmaceutical Companies
 
Preparing for an FDA Inspection
Preparing for an FDA InspectionPreparing for an FDA Inspection
Preparing for an FDA Inspection
 
Data integrity & ALCOA+
Data integrity & ALCOA+Data integrity & ALCOA+
Data integrity & ALCOA+
 
Good Documentation Practice (GDocP).pdf
Good Documentation Practice (GDocP).pdfGood Documentation Practice (GDocP).pdf
Good Documentation Practice (GDocP).pdf
 
Investigation of OOS and OOT results
Investigation of OOS and OOT resultsInvestigation of OOS and OOT results
Investigation of OOS and OOT results
 
Good Documentation Practice
Good Documentation PracticeGood Documentation Practice
Good Documentation Practice
 

Similar to FDA Audit - The Do and Don't List

Investigations august2012vpt
Investigations august2012vptInvestigations august2012vpt
Investigations august2012vptBill Forkey
 
The top 10 tips for dealing with employee problem behavior
The top 10 tips for dealing with employee problem behavior The top 10 tips for dealing with employee problem behavior
The top 10 tips for dealing with employee problem behavior khaneducation
 
Why people don't think rationally, Five types of Psychological Biases
Why people don't think rationally, Five types of Psychological BiasesWhy people don't think rationally, Five types of Psychological Biases
Why people don't think rationally, Five types of Psychological BiasesBabu Appat
 
Measuring the value of KM
Measuring the value of KMMeasuring the value of KM
Measuring the value of KMDavid Gurteen
 
How Buyer Personas Reveal the Whole Truth about Marketing Content & ROI
How Buyer Personas Reveal the Whole Truth about Marketing Content & ROIHow Buyer Personas Reveal the Whole Truth about Marketing Content & ROI
How Buyer Personas Reveal the Whole Truth about Marketing Content & ROIBuyer Persona Institute
 
Credibility and-your-legal-career
Credibility and-your-legal-careerCredibility and-your-legal-career
Credibility and-your-legal-careerBCG Attorney Search
 
Interview Iq
Interview IqInterview Iq
Interview Iqsjallred
 
Preparing Your FDA War Room
Preparing Your FDA War RoomPreparing Your FDA War Room
Preparing Your FDA War RoomDarshan Kulkarni
 
Interviewing Techniques
Interviewing TechniquesInterviewing Techniques
Interviewing Techniquesshowslides
 
10 Things You Should Not Do!!
10 Things You Should Not Do!!10 Things You Should Not Do!!
10 Things You Should Not Do!!Patel Chaitany R
 
Professional Etiquette And Do Donts
Professional Etiquette And Do DontsProfessional Etiquette And Do Donts
Professional Etiquette And Do DontsSouvik Santra
 
5 Reasons to Hire Field Investigation Agency.pptx
5 Reasons to Hire Field Investigation Agency.pptx5 Reasons to Hire Field Investigation Agency.pptx
5 Reasons to Hire Field Investigation Agency.pptxDebt Nirvana
 
Our 2020 Psychological Safety Survey Results
Our 2020 Psychological Safety Survey ResultsOur 2020 Psychological Safety Survey Results
Our 2020 Psychological Safety Survey ResultsStryve Digital Marketing
 
Performance appraisal interviews
Performance appraisal interviewsPerformance appraisal interviews
Performance appraisal interviewsritahenry316
 

Similar to FDA Audit - The Do and Don't List (20)

Investigations august2012vpt
Investigations august2012vptInvestigations august2012vpt
Investigations august2012vpt
 
The top 10 tips for dealing with employee problem behavior
The top 10 tips for dealing with employee problem behavior The top 10 tips for dealing with employee problem behavior
The top 10 tips for dealing with employee problem behavior
 
Soft skills
Soft skillsSoft skills
Soft skills
 
Why people don't think rationally, Five types of Psychological Biases
Why people don't think rationally, Five types of Psychological BiasesWhy people don't think rationally, Five types of Psychological Biases
Why people don't think rationally, Five types of Psychological Biases
 
L1 Work Readiness & Employment Bk Ck
L1 Work Readiness & Employment Bk CkL1 Work Readiness & Employment Bk Ck
L1 Work Readiness & Employment Bk Ck
 
Measuring the value of KM
Measuring the value of KMMeasuring the value of KM
Measuring the value of KM
 
How Buyer Personas Reveal the Whole Truth about Marketing Content & ROI
How Buyer Personas Reveal the Whole Truth about Marketing Content & ROIHow Buyer Personas Reveal the Whole Truth about Marketing Content & ROI
How Buyer Personas Reveal the Whole Truth about Marketing Content & ROI
 
Types of Interview.pptx
Types of Interview.pptxTypes of Interview.pptx
Types of Interview.pptx
 
Job Interview
Job InterviewJob Interview
Job Interview
 
Credibility and-your-legal-career
Credibility and-your-legal-careerCredibility and-your-legal-career
Credibility and-your-legal-career
 
Interview Iq
Interview IqInterview Iq
Interview Iq
 
Preparing Your FDA War Room
Preparing Your FDA War RoomPreparing Your FDA War Room
Preparing Your FDA War Room
 
Interviewing Techniques
Interviewing TechniquesInterviewing Techniques
Interviewing Techniques
 
10 Things You Should Not Do!!
10 Things You Should Not Do!!10 Things You Should Not Do!!
10 Things You Should Not Do!!
 
Professional Etiquette And Do Donts
Professional Etiquette And Do DontsProfessional Etiquette And Do Donts
Professional Etiquette And Do Donts
 
5 Reasons to Hire Field Investigation Agency.pptx
5 Reasons to Hire Field Investigation Agency.pptx5 Reasons to Hire Field Investigation Agency.pptx
5 Reasons to Hire Field Investigation Agency.pptx
 
Our 2020 Psychological Safety Survey Results
Our 2020 Psychological Safety Survey ResultsOur 2020 Psychological Safety Survey Results
Our 2020 Psychological Safety Survey Results
 
Top10 Questions
Top10 QuestionsTop10 Questions
Top10 Questions
 
Performance appraisal interviews
Performance appraisal interviewsPerformance appraisal interviews
Performance appraisal interviews
 
HR presentation
HR presentationHR presentation
HR presentation
 

More from Compliance Insight, Inc. (15)

July 2015
July 2015July 2015
July 2015
 
GCP Overview by Compliance Insight, Inc.
GCP Overview by Compliance Insight, Inc.GCP Overview by Compliance Insight, Inc.
GCP Overview by Compliance Insight, Inc.
 
FDA audit series part 5, dealing with the 483 or Warning Letter
FDA audit series   part 5, dealing with the 483 or Warning LetterFDA audit series   part 5, dealing with the 483 or Warning Letter
FDA audit series part 5, dealing with the 483 or Warning Letter
 
FDA audit series part 4, the closeout
FDA audit series   part 4, the closeoutFDA audit series   part 4, the closeout
FDA audit series part 4, the closeout
 
Fda audit series part 3, while the fda is there
Fda audit series   part 3, while the fda is  thereFda audit series   part 3, while the fda is  there
Fda audit series part 3, while the fda is there
 
FDA audit series part 2, what to do when the FDA arrives
FDA audit series   part 2, what to do when the FDA arrivesFDA audit series   part 2, what to do when the FDA arrives
FDA audit series part 2, what to do when the FDA arrives
 
FDA audit series part 1, Preparing for the Audit
FDA audit series   part 1, Preparing for the AuditFDA audit series   part 1, Preparing for the Audit
FDA audit series part 1, Preparing for the Audit
 
About Compliance Insight Inc.
About Compliance Insight Inc.About Compliance Insight Inc.
About Compliance Insight Inc.
 
FDA 483 observations in the lab
FDA 483 observations in the labFDA 483 observations in the lab
FDA 483 observations in the lab
 
Basics of FDA GMP Training
Basics of FDA GMP TrainingBasics of FDA GMP Training
Basics of FDA GMP Training
 
FDA GMP Training - The Quality Audit
FDA GMP Training - The Quality AuditFDA GMP Training - The Quality Audit
FDA GMP Training - The Quality Audit
 
Top 22 Tips: Writing For FDA Compliance
Top 22 Tips: Writing For FDA ComplianceTop 22 Tips: Writing For FDA Compliance
Top 22 Tips: Writing For FDA Compliance
 
21 cfr, parts 210 211
21 cfr, parts 210 21121 cfr, parts 210 211
21 cfr, parts 210 211
 
FDA Warning Letter
FDA Warning LetterFDA Warning Letter
FDA Warning Letter
 
FDA 483
FDA 483FDA 483
FDA 483
 

Recently uploaded

Annual General Meeting Presentation Slides
Annual General Meeting Presentation SlidesAnnual General Meeting Presentation Slides
Annual General Meeting Presentation SlidesKeppelCorporation
 
TriStar Gold Corporate Presentation - April 2024
TriStar Gold Corporate Presentation - April 2024TriStar Gold Corporate Presentation - April 2024
TriStar Gold Corporate Presentation - April 2024Adnet Communications
 
MAHA Global and IPR: Do Actions Speak Louder Than Words?
MAHA Global and IPR: Do Actions Speak Louder Than Words?MAHA Global and IPR: Do Actions Speak Louder Than Words?
MAHA Global and IPR: Do Actions Speak Louder Than Words?Olivia Kresic
 
Market Sizes Sample Report - 2024 Edition
Market Sizes Sample Report - 2024 EditionMarket Sizes Sample Report - 2024 Edition
Market Sizes Sample Report - 2024 EditionMintel Group
 
Digital Transformation in the PLM domain - distrib.pdf
Digital Transformation in the PLM domain - distrib.pdfDigital Transformation in the PLM domain - distrib.pdf
Digital Transformation in the PLM domain - distrib.pdfJos Voskuil
 
Pitch Deck Teardown: Geodesic.Life's $500k Pre-seed deck
Pitch Deck Teardown: Geodesic.Life's $500k Pre-seed deckPitch Deck Teardown: Geodesic.Life's $500k Pre-seed deck
Pitch Deck Teardown: Geodesic.Life's $500k Pre-seed deckHajeJanKamps
 
Independent Call Girls Andheri Nightlaila 9967584737
Independent Call Girls Andheri Nightlaila 9967584737Independent Call Girls Andheri Nightlaila 9967584737
Independent Call Girls Andheri Nightlaila 9967584737Riya Pathan
 
Traction part 2 - EOS Model JAX Bridges.
Traction part 2 - EOS Model JAX Bridges.Traction part 2 - EOS Model JAX Bridges.
Traction part 2 - EOS Model JAX Bridges.Anamaria Contreras
 
Ten Organizational Design Models to align structure and operations to busines...
Ten Organizational Design Models to align structure and operations to busines...Ten Organizational Design Models to align structure and operations to busines...
Ten Organizational Design Models to align structure and operations to busines...Seta Wicaksana
 
8447779800, Low rate Call girls in Rohini Delhi NCR
8447779800, Low rate Call girls in Rohini Delhi NCR8447779800, Low rate Call girls in Rohini Delhi NCR
8447779800, Low rate Call girls in Rohini Delhi NCRashishs7044
 
Global Scenario On Sustainable and Resilient Coconut Industry by Dr. Jelfina...
Global Scenario On Sustainable  and Resilient Coconut Industry by Dr. Jelfina...Global Scenario On Sustainable  and Resilient Coconut Industry by Dr. Jelfina...
Global Scenario On Sustainable and Resilient Coconut Industry by Dr. Jelfina...ictsugar
 
Memorándum de Entendimiento (MoU) entre Codelco y SQM
Memorándum de Entendimiento (MoU) entre Codelco y SQMMemorándum de Entendimiento (MoU) entre Codelco y SQM
Memorándum de Entendimiento (MoU) entre Codelco y SQMVoces Mineras
 
Flow Your Strategy at Flight Levels Day 2024
Flow Your Strategy at Flight Levels Day 2024Flow Your Strategy at Flight Levels Day 2024
Flow Your Strategy at Flight Levels Day 2024Kirill Klimov
 
Financial-Statement-Analysis-of-Coca-cola-Company.pptx
Financial-Statement-Analysis-of-Coca-cola-Company.pptxFinancial-Statement-Analysis-of-Coca-cola-Company.pptx
Financial-Statement-Analysis-of-Coca-cola-Company.pptxsaniyaimamuddin
 
8447779800, Low rate Call girls in New Ashok Nagar Delhi NCR
8447779800, Low rate Call girls in New Ashok Nagar Delhi NCR8447779800, Low rate Call girls in New Ashok Nagar Delhi NCR
8447779800, Low rate Call girls in New Ashok Nagar Delhi NCRashishs7044
 
Guide Complete Set of Residential Architectural Drawings PDF
Guide Complete Set of Residential Architectural Drawings PDFGuide Complete Set of Residential Architectural Drawings PDF
Guide Complete Set of Residential Architectural Drawings PDFChandresh Chudasama
 
NewBase 19 April 2024 Energy News issue - 1717 by Khaled Al Awadi.pdf
NewBase  19 April  2024  Energy News issue - 1717 by Khaled Al Awadi.pdfNewBase  19 April  2024  Energy News issue - 1717 by Khaled Al Awadi.pdf
NewBase 19 April 2024 Energy News issue - 1717 by Khaled Al Awadi.pdfKhaled Al Awadi
 
8447779800, Low rate Call girls in Shivaji Enclave Delhi NCR
8447779800, Low rate Call girls in Shivaji Enclave Delhi NCR8447779800, Low rate Call girls in Shivaji Enclave Delhi NCR
8447779800, Low rate Call girls in Shivaji Enclave Delhi NCRashishs7044
 

Recently uploaded (20)

Annual General Meeting Presentation Slides
Annual General Meeting Presentation SlidesAnnual General Meeting Presentation Slides
Annual General Meeting Presentation Slides
 
TriStar Gold Corporate Presentation - April 2024
TriStar Gold Corporate Presentation - April 2024TriStar Gold Corporate Presentation - April 2024
TriStar Gold Corporate Presentation - April 2024
 
MAHA Global and IPR: Do Actions Speak Louder Than Words?
MAHA Global and IPR: Do Actions Speak Louder Than Words?MAHA Global and IPR: Do Actions Speak Louder Than Words?
MAHA Global and IPR: Do Actions Speak Louder Than Words?
 
Market Sizes Sample Report - 2024 Edition
Market Sizes Sample Report - 2024 EditionMarket Sizes Sample Report - 2024 Edition
Market Sizes Sample Report - 2024 Edition
 
Digital Transformation in the PLM domain - distrib.pdf
Digital Transformation in the PLM domain - distrib.pdfDigital Transformation in the PLM domain - distrib.pdf
Digital Transformation in the PLM domain - distrib.pdf
 
Pitch Deck Teardown: Geodesic.Life's $500k Pre-seed deck
Pitch Deck Teardown: Geodesic.Life's $500k Pre-seed deckPitch Deck Teardown: Geodesic.Life's $500k Pre-seed deck
Pitch Deck Teardown: Geodesic.Life's $500k Pre-seed deck
 
Independent Call Girls Andheri Nightlaila 9967584737
Independent Call Girls Andheri Nightlaila 9967584737Independent Call Girls Andheri Nightlaila 9967584737
Independent Call Girls Andheri Nightlaila 9967584737
 
Traction part 2 - EOS Model JAX Bridges.
Traction part 2 - EOS Model JAX Bridges.Traction part 2 - EOS Model JAX Bridges.
Traction part 2 - EOS Model JAX Bridges.
 
Japan IT Week 2024 Brochure by 47Billion (English)
Japan IT Week 2024 Brochure by 47Billion (English)Japan IT Week 2024 Brochure by 47Billion (English)
Japan IT Week 2024 Brochure by 47Billion (English)
 
Ten Organizational Design Models to align structure and operations to busines...
Ten Organizational Design Models to align structure and operations to busines...Ten Organizational Design Models to align structure and operations to busines...
Ten Organizational Design Models to align structure and operations to busines...
 
8447779800, Low rate Call girls in Rohini Delhi NCR
8447779800, Low rate Call girls in Rohini Delhi NCR8447779800, Low rate Call girls in Rohini Delhi NCR
8447779800, Low rate Call girls in Rohini Delhi NCR
 
Global Scenario On Sustainable and Resilient Coconut Industry by Dr. Jelfina...
Global Scenario On Sustainable  and Resilient Coconut Industry by Dr. Jelfina...Global Scenario On Sustainable  and Resilient Coconut Industry by Dr. Jelfina...
Global Scenario On Sustainable and Resilient Coconut Industry by Dr. Jelfina...
 
Memorándum de Entendimiento (MoU) entre Codelco y SQM
Memorándum de Entendimiento (MoU) entre Codelco y SQMMemorándum de Entendimiento (MoU) entre Codelco y SQM
Memorándum de Entendimiento (MoU) entre Codelco y SQM
 
Flow Your Strategy at Flight Levels Day 2024
Flow Your Strategy at Flight Levels Day 2024Flow Your Strategy at Flight Levels Day 2024
Flow Your Strategy at Flight Levels Day 2024
 
Financial-Statement-Analysis-of-Coca-cola-Company.pptx
Financial-Statement-Analysis-of-Coca-cola-Company.pptxFinancial-Statement-Analysis-of-Coca-cola-Company.pptx
Financial-Statement-Analysis-of-Coca-cola-Company.pptx
 
8447779800, Low rate Call girls in New Ashok Nagar Delhi NCR
8447779800, Low rate Call girls in New Ashok Nagar Delhi NCR8447779800, Low rate Call girls in New Ashok Nagar Delhi NCR
8447779800, Low rate Call girls in New Ashok Nagar Delhi NCR
 
Guide Complete Set of Residential Architectural Drawings PDF
Guide Complete Set of Residential Architectural Drawings PDFGuide Complete Set of Residential Architectural Drawings PDF
Guide Complete Set of Residential Architectural Drawings PDF
 
NewBase 19 April 2024 Energy News issue - 1717 by Khaled Al Awadi.pdf
NewBase  19 April  2024  Energy News issue - 1717 by Khaled Al Awadi.pdfNewBase  19 April  2024  Energy News issue - 1717 by Khaled Al Awadi.pdf
NewBase 19 April 2024 Energy News issue - 1717 by Khaled Al Awadi.pdf
 
Corporate Profile 47Billion Information Technology
Corporate Profile 47Billion Information TechnologyCorporate Profile 47Billion Information Technology
Corporate Profile 47Billion Information Technology
 
8447779800, Low rate Call girls in Shivaji Enclave Delhi NCR
8447779800, Low rate Call girls in Shivaji Enclave Delhi NCR8447779800, Low rate Call girls in Shivaji Enclave Delhi NCR
8447779800, Low rate Call girls in Shivaji Enclave Delhi NCR
 

FDA Audit - The Do and Don't List

  • 1. Do’s and Don’ts During An FDA Inspection Copyrighted 2013 Compliance Insight, Inc.
  • 2. When dealing with the FDA investigator, we should demonstrate knowledge of and confidence in our quality system. Not arrogant nor defiant… The DO’s During an Inspection Copyrighted 2013 Compliance Insight, Inc.
  • 3. * Never give false data, always tell the truth * Is it OK to say “I don’t know”? * The investigator may ask the same question to different people at different times The DON’Ts During an Inspection Copyrighted 2013 Compliance Insight, Inc.
  • 4. The DON’Ts During an Inspection  There are some “tricks” used to pull information from you during the audit  Be aware of what you are saying and doing  The “dome of silence”  The tendency of people to try to fill a void with more information  Talk, offer more info  The “Hmmm… factor”  Ask a question, write it down, shake your head or get a concerned look  People take this as a “problem” and then offer more info to fill the gap Copyrighted 2013 Compliance Insight, Inc.
  • 5. If the investigator asks you for some information, do not: * make them ask for it again * wait to see if they forget about the request The DON’Ts During an Inspection Copyrighted 2013 Compliance Insight, Inc.
  • 6. * It is not productive to argue with the investigator when responding to a question or observation * Don’t challenge the investigator. There is no need for that. It only motivates curiosity and questions. The DON’Ts During an Inspection Copyrighted 2013 Compliance Insight, Inc.
  • 7. * Do not stand around making faces and looking worried. This makes people feel nervous and may alert the investigator that something may be wrong. * Act confident and proud, not defensive. * If a fellow employee is being questioned, do not try to help them by answering the questions yourself or by giving contradictory information. The DON’Ts During an Inspection Copyrighted 2013 Compliance Insight, Inc.
  • 8. * Do not interrupt the investigator or other employees when they are speaking * Do not talk loud or speak with the others when the investigator is trying to concentrate, read or review documentation. * It is not your job to fill an uncomfortable silence with additional explanation. The DON’Ts During an Inspection Copyrighted 2013 Compliance Insight, Inc.
  • 9. The DON’Ts During an Inspection Loos e lips sink ships Don’t talk – even off site!!! Copyrighted 2013 Compliance Insight, Inc.
  • 10. Things To Remember During An FDA Inspection Copyrighted 2013 Compliance Insight, Inc.
  • 11. * If it isn’t documented, it doesn’t exist Things to Remember During an Audit Copyrighted 2013 Compliance Insight, Inc.
  • 12. * Investigator may “read” your body language * Be aware of your body language Things to Remember During an Audit Copyrighted 2013 Compliance Insight, Inc.
  • 13. * During the inspection, observe and learn to “read” the Investigator’s body language. Things to Remember During an Audit Copyrighted 2013 Compliance Insight, Inc.
  • 14. * Verbal ~7% * Paralinguistic ~38% * Non-Verbal ~55% Communication Copyrighted 2013 Compliance Insight, Inc.
  • 15. * Intimate zone 0-1½ ft. * Personal zone1½-4 ft. * Social zone 4-12 ft. Interview Orientation Copyrighted 2013 Compliance Insight, Inc.
  • 16. * Establish the “normal” behavior patterns So that you are aware of behavioral changes Interview Techniques Copyrighted 2013 Compliance Insight, Inc.
  • 17. * Upright * Open & Relaxed * Lean forward on occasion * Aligned with Investigator * Casual Posture Change Truthful Posture Copyrighted 2013 Compliance Insight, Inc.
  • 18. * Retreating * Slouching * Frozen * Not aligned * Barrier Posture * Consistent posture changes * Head & Body Slump Deceptive Posture Copyrighted 2013 Compliance Insight, Inc.
  • 19. * Composed * Concerned/Realistic * Cooperative * Direct/Spontaneous * Open/Helpful * Sincere * Confident * Persistent/Consistent Truthful Behaviors Copyrighted 2013 Compliance Insight, Inc.
  • 20. * Overly Anxious * Unconcerned/Unrealistic * Uncooperative/Defensive * Guarded/Evasive/Hesitant * Rationalizing/Unhelpful * Insincere * Defeated * Apologetic/Accepting * Quiet Deceptive Behaviors Copyrighted 2013 Compliance Insight, Inc.
  • 21. Breaking a Gaze Right = edit or fabricate Left = access memory I wonder if he’ll believe this? Yes, that is how it was done About 85% accurate but use only as a tool to determine if further questions need to beCopyrighted 2013 Compliance Insight, Inc.
  • 22. * Stick to the facts not opinions. Do not use phrases such as: I think … I’m not sure but … In my opinion, it should … What you are saying is not true… Honestly… Usually… Typically… As I recall… Things to Remember During an Audit Copyrighted 2013 Compliance Insight, Inc.
  • 23. * Listen to questions carefully * Answer only what is asked. Do not volunteer information * Clarify what you don’t understand before answering the question * When a question is too broad, ask for specifics Things to Remember During an Audit Copyrighted 2013 Compliance Insight, Inc.
  • 24. * If you don’t know the answer, say so. It is all right to say that you need to look into the situation further before answering. * Do not guess if you’re not sure of the answer. Look it up in the procedure and or consult you peers, or another SME. * If you are not a SME for a question asked, do not answer the question and explain to FDA this fact and get the right person. Things to Remember During an Audit Copyrighted 2013 Compliance Insight, Inc.
  • 25. If you think that the investigator has misunderstood something * say so immediately * explain why in a professional manner Things to Remember During an Audit Copyrighted 2013 Compliance Insight, Inc.
  • 26. Phrases to Refrain From! * That’s the way we’ve always done it * Off the record… * I probably shouldn’t say this but… * Who, me? * … Uh, no * It’s probably a mistake. Copyrighted 2013 Compliance Insight, Inc.
  • 27. * If we would do it that way we would never get anything done * We don’t have enough time or resources to follow that procedure * I do it a different way because the procedure is not good * If you think that’s bad you should see this... * We fixed that problem by firing the person * That’s not my fault, that was the previous supervisor … * That’s not my problem, that’s Quality Assurance’s problem * Write it on the FDA-483, it’s the only way we can correct it. Phrases to Refrain From! Copyrighted 2013 Compliance Insight, Inc.
  • 28. Documents and Records The investigator is permitted to review :  Documents and records pertaining to the control, manufacturing or quality assurance activities within the facility, as required by applicable federal regulations.  These include (but are not limited to):  Procedures  Batch Records  Regulatory Filings  Quality Control Procedures  Validation records  Calibration/PM records  Investigations  Other records such as training records, job descriptions, procedures, promotional labeling etc., as defined in relevant parts of the FDA regulation unless otherwise specified. Documents that can not be reviewed by FDA:  Reports of audits performed by internal auditors, customers, external auditors or consultants  Records and documents pertaining to the financial matters of the company (sales data, pricing information, etc.)  Research data/protocols (true “research” data is exempt from review, product development data can be reviewed by FDA)  Personnel records other than training  Management review meeting minutes Copyrighted 2013 Compliance Insight, Inc.
  • 29. What happens if an investigator finds something wrong? Answer:  Discuss concern/finding with investigator so you fully understand what the investigator understands. There should be no misconceptions. Ask questions.  At the end of each day, we request an oral list of all observations. This gives us an opportunity to address issues before the close of the inspection and allows us to prepare responses to potential 483 observations.  At the conclusion of the inspection, the investigator presents significant findings at the closing meeting on a FDA 483, List of Observations.  If the findings are minor, the investigator may opt to do nothing except verbally advise the Regulatory representative and management of the concerns. Frequently Asked Questions Copyrighted 2013 Compliance Insight, Inc.
  • 30. What happens if an investigator find something wrong? Answer (continued):  Your firm will respond in writing to the Form 483 with a corrective action plan.  We have to act quickly but effectively.  Corrective Action Plan should address specific observations, systemic correction and time frame for implementing corrective actions. Frequently Asked Questions Copyrighted 2013 Compliance Insight, Inc.
  • 31. Compliance Insight, Inc. 513-860-3512 For a Free Consultation www.Compliance-Insight.com Copyrighted 2013 Compliance Insight, Inc.